Company: WKC
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058752
Chunk: 69

Company: WORLD KINECT CORP
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 69
---
 awards will be granted under the 2021 Plan; however, outstanding awards under the 2021 Plan will continue to be governed by the terms of the 2021 Plan until exercised, settled, expired or otherwise terminated or canceled. If the 2025 Plan is approved, the number of shares of Stock that will be available for issuance under the 2025 Plan pursuant to any form of equity awards permitted under the 2025 Plan will be equal to the sum of (a) 1.85 million shares of Stock; plus (b) any shares of Stock remaining available for future awards under the 2021 Plan on the date the 2025 Plan is approved by the Company’s shareholders (of which there were 1.3 million shares of Stock remaining available for future awards under the 2021 Plan as of March 31, 2025); plus (c) any shares of Stock with respect to awards that were granted under the 2025 Plan, the 2021 Plan, our 2020 Omnibus Plan (the "2020 Plan"), our 2016 Omnibus Plan (the "2016 Plan") or our 2006 Omnibus Plan (the "2006 Plan" and together with the 2016 Plan, 2020 Plan and 2021 Plan, the "Prior Plans') that are forfeited or canceled (e.g., due to the recipient’s failure to satisfy applicable service or performance conditions) after the 2025 Plan is approved by the Company’s shareholders. However, shares of Stock with respect to awards under the 2025 Plan or the Prior Plans that are withheld or tendered or not issued to a participant (or otherwise used) to satisfy tax withholding obligations or to pay the exercise price of an award under the 2025 Plan or any award under the Prior Plans would not become available for issuance pursuant to the 2025 Plan. If the 2025 Plan is not approved by our shareholders, no awards will be made under the 2025 Plan, and the 2021 Plan will remain in effect pursuant to its terms.

Why We Recommend That You Vote for this Proposal

The 2025 Plan authorizes the Committee to provide equity-based compensation, including in the form of stock options, stock appreciation rights (“SARs”), stock unit awards, performance-based compensation awards, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), dividend equivalents and certain other awards denominated or payable in, or otherwise based on, shares of Stock (or factors